Abstract
A 49-year-old female was referred to our hospital with left breast cancer and subsequently underwent mastectomy and axillary dissection. The pathological findings showed invasive breast cancer with lymph node metastasis (2/22), nuclear grade 3, ER (6+) PgR (2+) for the Allred score, and Her2 (2+) in an immunohistochemistry. We determined the subtype of Her2-negative breast cancer according to the fluorescent in situ hybridization results, as follows: Her2/CEP17 ratio 1.1 < 2.0. The patient received the EC regimen followed by docetaxel, and toremifene was subsequently administered. One year after the operation, the CA15-3 level was elevated at 50 ng/ml, and CT revealed liver metastases. Disease progression was not suppressed by paclitaxel containing regimen and eribulin. Then, we subsequently sought to determine whether the metastatic lesion showed the Her2 expression. Although the Her2 expression in the axillary lymph node metastases showed heterogeneous staining, the results were judged as Her2 (1+) according to the ASCO/CAP guidelines. We decided to administer trastuzumab and docetaxel due to the patient’s life-threatening status, after which the CA15-3 level decreased and the symptom of fatigue improved. A total of 9 cycles of trastuzumab and docetaxel were administered, followed by maintenance trastuzumab continued to the present time. Physicians should be aware of the statement in the ASCO/CAP guidelines that the clinical decision to ultimately consider Her2-targeted therapy should be individualized according to the patient’s status.
Similar content being viewed by others
References
Slamon DJ, Leyland-Jones B, Shak S et al (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344:783–792
Moja L, Tagliabue L, Balduzzi S et al (2012) Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev 4:CD006243
Valachis A, Mauri D, Polyzos NP et al (2011) Trastuzumab combined to neoadjuvant chemotherapy in patients with HER2-positive breast cancer: a systematic review and meta-analysis. Breast 20:485–490
Gianni L, Eiermann W, Semiglazov V et al (2010) Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet 375:377–384
Wolff AC, Hammond ME, Schwartz JN et al (2007) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 25:118–145
Ardavanis A, Kountourakis P, Kyriakou F et al (2008) Trastuzumab plus paclitaxel or docetaxel in HER-2-negative/HER-2 ECD-positive anthracycline- and taxane-refractory advanced breast cancer. Oncologist 13:361–369
Wolff AC, Hammond ME, Hicks DG et al (2013) Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997–4013
Gown AM (2008) Current issues in ER and HER2 testing by IHC in breast cancer. Mod Pathol 21(Suppl 2):S8–S15
Heitz F, Barinoff J, du Bois O et al (2013) Differences in the receptor status between primary and recurrent breast cancer—the frequency of and the reasons for discordance. Oncology 84:319–325
Curtit E, Nerich V, Mansi L et al (2013) Discordances in estrogen receptor status, progesterone receptor status, and HER2 status between primary breast cancer and metastasis. Oncologist 18:667–674
Turner NH, Di Leo A (2013) HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact. Cancer Treat Rev 39:947–957
Guarneri V, Dieci MV, Barbieri E et al (2013) Loss of HER2 positivity and prognosis after neoadjuvant therapy in HER2-positive breast cancer patients. Ann Oncol 24:2990–2994
Aurilio G, Disalvatore D, Pruneri G et al (2014) A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer 50:277–289
Yao ZX, Lu LJ, Wang RJ et al (2014) Discordance and clinical significance of ER, PR, and HER2 status between primary breast cancer and synchronous axillary lymph node metastasis. Med Oncol 31:798
Krishnamurthy S, Bischoff F, Ann Mayer J et al (2013) Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer. Cancer Med 2:226–233
Carney WP, Neumann R, Lipton A et al (2004) Monitoring the circulating levels of the HER2/neu oncoprotein in breast cancer. Clin Breast Cancer 5:105–116
Barron JJ, Cziraky MJ, Weisman T et al (2009) HER2 testing and subsequent trastuzumab treatment for breast cancer in a managed care environment. Oncologist 14:760–768
Conflict of interest
The authors declare no conflicts of interest (COI).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Takahashi, K., Nakagomi, H., Inoue, M. et al. Life-threatening metastasis was suppressed by trastuzumab containing regimen in a patient with Her2-negative breast cancer. Int Canc Conf J 5, 61–65 (2016). https://doi.org/10.1007/s13691-015-0228-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13691-015-0228-4